Low CMV and EBV infections in the era of letermovir with post-transplantation cyclophosphamide combined with tacrolimus and low-dose post engraftment ATG as gvhd prophylaxis. (ASH 2025) - Nov 4, 2025 - Abstract #abs25-10369; 4271; Pres time: Dec 7, 2025; 06:00 PM - 08:00 PM; Location: OCCC - West Halls B3-B4; "Overall, the NRM was significantly lower in the LTV group (4.3 % vs 14.2 %, p=0.01), yielding superior OS(94.5 % vs 79.9 %, p=0.004) and DFS (83.9 % vs 73.7 %, p=0.008), while the relapse incidence did not differ(p=0.64).ConclusionsIn the context of PTCy, tacrolimus and low-dose ATG as GVHD prophylaxis, LTV effectively prevents earlyCMV infection without increasing the risk of EBV reactivation or PTLD. These findings support LTV as aneffective antiviral prophylaxis in allo-HSCT and suggest its use contributes to improved transplantationoutcomes."
Post-transplantation • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Transplantation
|
|
Wenhui Gao1; Lining Wang1; ling Wang1; Jieling Jiang1; Jiong Hu1
|